Logo

Prestige Biopharma Entered into a Binding Agreement with Intas to Commercialize HD204 (biosimilar, bevacizumab) in Multiple Countries

Share this
Prestige Biopharma Entered into a Binding Agreement with Intas to Commercialize HD204 (biosimilar, bevacizumab) in Multiple Countries

Prestige Biopharma Entered into a Binding Agreement with Intas to Commercialize HD204 (biosimilar, bevacizumab) in Multiple Countries

Shots:

  • Intas & its affiliate Accord will get exclusive rights for the commercialization of bevacizumab biosimilar in the US, EU, Canada, MENA, Brazil, Mexico, South Africa, Thailand, Vietnam, Philippines, Malaysia, Singapore, Indonesia, Kyrgyzstan & Tajikistan. Prestige will lead the development & distribution
  • The collaboration aims to broaden market reach in the EU & Canada using Accord's robust global footprint & in-depth commercial expertise
  • Bevacizumab is used in combination with other therapies for multiple cancer incl. metastatic colorectal cancer, NSCLC, kidney cancer & others. HD204 is being evaluated in the P-III (SAMSON-II) trial with expected plans for filing applications with regulatory authorities in the US & EU in 2023

Ref: PR Newswire | Image: Prestige Biopharma 

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions